Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
RNAZ 
Transcode Therapeutics Inc (RNAZ)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/10/2025: RNAZ (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10
1 Year Target Price $10
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -87.58% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 12.98M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 1 | Beta 1.51 | 52 Weeks Range 6.15 - 720.72 | Updated Date 10/12/2025 |
52 Weeks Range 6.15 - 720.72 | Updated Date 10/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -61.43 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -139.89% | Return on Equity (TTM) -658.62% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3047593 | Price to Sales(TTM) - |
Enterprise Value 3047593 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.59 | Shares Outstanding 916968 | Shares Floating 832424 |
Shares Outstanding 916968 | Shares Floating 832424 | ||
Percent Insiders 0.14 | Percent Institutions 4.03 |
Upturn AI SWOT
Transcode Therapeutics Inc
Company Overview
History and Background
Transcode Therapeutics, Inc., founded in 2010, focuses on developing RNA therapeutics for cancer. It transitioned from a diagnostics company to a drug development company, aiming to revolutionize cancer treatment with its TTX delivery platform.
Core Business Areas
- RNA Oncology: Develops RNA-based therapeutics for cancer treatment, focusing on utilizing their proprietary TTX delivery platform to target tumors effectively. Primarily focuses on solid tumors.
Leadership and Structure
The leadership team includes Michael McGuire (CEO) and other executives overseeing research, development, and operations. The structure involves a board of directors and various departments focused on drug development and clinical trials.
Top Products and Market Share
Key Offerings
- TTX Technology Platform: Transcode's primary asset is its TTX platform, a non-viral delivery system for RNA therapeutics. This is still in development, with lead drug candidate TTX-MC138 in clinical trials. As it is in early stages, there's no market share. Competitors include companies developing RNA therapeutics using lipid nanoparticles (e.g., Alnylam, Moderna, BioNTech).
- TTX-MC138: Their lead drug candidate for treating metastatic cancer. It is currently undergoing Phase 0 and Phase 1 clinical trials in patients with advanced solid tumors. As it is in early stages, there's no market share and no revenue from the product. Competitors include companies developing similar RNA-based cancer therapies and conventional chemotherapy drugs.
Market Dynamics
Industry Overview
The RNA therapeutics market is rapidly growing, driven by advancements in delivery technologies and the potential to target previously undruggable targets. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms.
Positioning
Transcode is positioned as a specialist in RNA delivery for oncology. Its TTX platform aims to offer improved targeting and reduced toxicity compared to traditional methods.
Total Addressable Market (TAM)
The global oncology market is substantial, estimated at hundreds of billions of dollars annually. The addressable market for RNA therapeutics within oncology is growing, with estimates varying depending on disease and treatment modality. Transcode is positioned to capture a portion of this growing market with successful trials.
Upturn SWOT Analysis
Strengths
- Proprietary TTX delivery platform
- Focus on RNA therapeutics for cancer
- Lead drug candidate in clinical trials
Weaknesses
- Early-stage development (high risk)
- Limited financial resources
- Dependence on TTX platform success
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of TTX platform to other therapeutic areas
- Positive clinical trial results
Threats
- Clinical trial failures
- Competition from established players
- Regulatory hurdles
- Funding challenges
Competitors and Market Share
Key Competitors
- ALNY
- MRNA
- BNTX
Competitive Landscape
Transcode faces significant competition from established pharmaceutical and biotech companies with greater resources and advanced pipelines. Its competitive advantage lies in its proprietary TTX delivery platform, which aims to overcome limitations of existing delivery methods.
Growth Trajectory and Initiatives
Historical Growth: Limited historical growth in terms of revenue. Growth is focused on preclinical and clinical progress of pipeline candidates.
Future Projections: Future growth is highly dependent on successful clinical trial outcomes and potential partnerships. Analyst estimates vary.
Recent Initiatives: Focus on advancing TTX-MC138 through clinical trials, exploring new applications of the TTX platform.
Summary
Transcode Therapeutics is an early-stage biotech company with a promising RNA delivery platform. Its strength lies in its innovative TTX technology, but it faces challenges related to funding and clinical trial risks. Successful clinical trials and strategic partnerships are crucial for its future growth and sustainability. It must focus on proving its technology for its pipeline to deliver shareholder value.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Press releases
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual research and consultation with a financial professional. Market share percentages are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Transcode Therapeutics Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-07-08 | CEO & Executive Chairman of the Board Dr. Philippe P. Calais Ph.D., Pharm., Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | |
Full time employees 7 | |||
TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.